Douglas Pharmaceuticals Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Douglas Pharmaceuticals Limited
US FDA Asks Manufacturers To Fix Disruption In Isotretinoin REMS
The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.
Pfizer sells Icagen drug discovery, not compounds
Four years after Pfizer acquired Icagen for $56m, the big pharma sold the drug discovery firm to XRpro Sciences for up to $11m, which would seem to be a big discount if the deal gave the buyer access to compounds generated by Icagen's ion channel biology platform.
FDA guides on abuse-deterrent opioids; generics direction pending
The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.
INTERVIEW: Actavis CEO Saunders staying put as Allergan deal nears close
Actavis CEO Brent Saunders has been the head of three different companies in less than two years, but with the $66bn acquisition of Allergan about to close any day now, he told Scrip that he's found the place where he plans to retire.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.